Ciprofibrate, a hypolipidemic drug that acts as a peroxisome proliferator, induces the transcription of genes encoding peroxisomal (oxidation enzymes. To identify cisacting promoter elements involved in this induction, 5.8 kilobase pairs of promoter sequence from the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (EC 4.2
a luciferase reporter gene. Transfection of this expression vector into rat hepatoma H4IIEC3 cells in the presence of ciprofibrate resulted in a 5-to 10-fold, cell type-specific increase in luciferase activity as compared to cells transfected in the absence of drug. A peroxisome proliferator-responsive element (PPRE) was localized to a 196-nucleotide region centered at position -2943 from the transcription start site. This PPRE conferred ciprofibrate responsiveness on a heterologous promoter and functioned independently of orientation or position. Gel retardation analysis with nuclear extracts demonstrated that ciprofibrate-treated or untreated H4IIEC3 cells, but not HeLa cells or monkey kidney cells, contained sequencespecific DNA binding factors that interact with the PPRE. These results have implications for understanding the mechanisms of coordinated transcriptional induction of genes encoding peroxisomal proteins by hypolipidemic agents and other peroxisome proliferators.
Peroxisomes are organelles that perform biological oxidative functions, notably the H202-generating 13-oxidation of fatty acids (1) . Administration of a diverse group of xenobiotic chemical compounds referred to as peroxisome proliferators results in a dramatic increase in both the number and the metabolic capacity of hepatic peroxisomes (2, 3) . Within this group are various hypolipidemic drugs used in the treatment of ischemic heart disease and in controlling elevated levels of circulating triacylglycerols and cholesterol (4) (5) (6) . Drugs like clofibrate and ciprofibrate are peroxisome proliferators that elicit a number of related pleiotropic effects, including hepatomegaly and hepatocarcinogenesis in rodents (2) (3) (4) 7) . These agents are classified as non-genotoxic carcinogens, as they are not directly mutagenic and do not damage DNA (8, 9 ).
Concomitant with drug-induced peroxisome proliferation is the rapid and coordinated induction of the enzymes of the peroxisomal fatty acid (-oxidation system: H202-generating fatty acyl-CoA oxidase (AOX), enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD) bifunctional enzyme, and 3-ketoacyl-CoA thiolase (10) (11) (12) . The increased activities of these enzymes are related to the rapid transcriptional activation of the nuclear genes encoding these enzymes (13) (14) (15) . Transcriptional activation is apparently mediated through members of the nuclear hormone receptor superfamily that can be activated by peroxisome proliferators (16) (17) (18) and have been designated peroxisome proliferatoractivated receptors (PPARs).
We report the presence of an enhancer-like peroxisome proliferator-responsive element (PPRE) upstream of the HD gene and demonstrate that this PPRE interacts with liverspecific factors in a sequence-dependent mannery MATERIALS AND METHODS Cells. Rat hepatoma H4IIEC3 cells were cultured as monolayers in Dulbecco's modified minimal essential medium plus 10% horse serum and 5% fetal bovine serum. BSC40 cells were maintained in Dulbecco's modified minimal essential medium plus 10% calf serum. HeLa cells were maintained in suspension in Joklik's modified medium plus 5% fetal bovine serum.
Plasmids and Construction of Promoter Deletion Mutants. pHDLuc was constructed by inserting a 5.8-kilobase-pair (kbp) promoter fragment from the rat HD gene as a Kpn I-Apa I fragment into the luciferase expression vector pSVOALA5' (19) . The HD promoter fragment extends to +22 from the transcription start site (20) . For the construction of deletion mutants, the Kpn I-Apa I fragment was inserted into pGEM-7Zf(+) (Promega). Deletion mutants were constructed using selected restriction sites and reinserted into pSVOALA5' as Kpn I-Apa I fragments. pCPSLuc is a luciferase expression vector containing the minimal promoter for the gene encoding rat liver carbamoyl-phosphate synthetase (CPS; ref. 21) . Subfragments of the HD promoter were inserted into the BamHI site of pCPSLuc. DNA fragments were amplified by the polymerase chain reaction (PCR) using combinations of oligonucleotide primers [1] [2] [3] [4] [5] [6] The numbers in parentheses refer to the positions of the 5' nucleotides in the amplification target (see Fig. 3 ). The underlined sequences were added to incorporate either a Bgl II site (forward primers) or a BamHI site (reverse primers).
pRSVcat and pCH11O (Pharmacia) are reporter plasmids expressing the genes encoding Escherichia coli chloramphenicol acetyltransferase and f-galactosidase, respectively (22, 23) .
Transfections. Transfections were done by a modification of the calcium phosphate procedure (24) with H4IIEC3 cells at 60-70%o confluence in 10-cm dishes. A calcium phosphate/ DNA coprecipitate suspension (2 ml) was made containing plasmid at 30 pg/ml and sonicated salmon sperm DNA at 10 pg/ml. The suspension was divided into 0.5-ml aliquots and added dropwise to cells incubated in the presence of 10 ml of freshly added medium containing either 0.5 mM ciprofibrate (100 mM stock solution in dimethyl sulfoxide) or 0.5% dimethyl sulfoxide alone. After incubation at 370C for 16 hr, medium was replaced with appropriately supplemented fresh medium, and incubation was continued for an additional 24 hr. Cells were washed with phosphate-buffered saline, and extracts were prepared by suspension ofthe cell pellets in 100 ,.l of lysis solution [25 mM Tris phosphate, pH 7.8/2 mM dithiothreitol/2 mM 1,2-diaminocyclohexane-NN,N',N'-tetraacetic acid, 10%o (wt/vol) glycerol, 1% (wt/vol) Triton X-100], followed by vortex mixing. Cell debris was removed by centrifugation, and the supernatant was assayed for luciferase activity with a luminometer (model 1253, Bio-Orbit Oy, Turku, Finland) and a luciferase activity kit (Promega) (19) . Chloramphenicol acetyltransferase and ,3-galactosidase were assayed as described (25, 26) . Protein was determined by the method of Bradford (27) .
Gel Retardation Analysis. Nuclear extracts from HeLa cells were prepared from cell suspensions (28) . Nuclear extracts from BSC40 and H4IIEC3 cells were prepared from monolayer cultures (29, 30) . Nuclear extracts were also prepared from H4IIEC3 cells cultured for 48 hr in the presence ofeither 0.5 mM ciprofibrate or 0.5% dimethyl sulfoxide.
Gel retardation assays were performed as described (31, 32) . Probe DNA [promoter coordinates -3040 to -2845 (see Fig. 3 As seen in Fig. 1, sequential As shown in Fig. 2 , the region between -3178 and -2281 conferred inducibility on the minimal CPS promoter. Therefore, this region contains a positively acting PPRE that functions independently of other regions of the HD promoter. The PPRE displayed enhancer-like properties in that it functioned in a position-and orientation-independent manner (plasmid b in Fig. 2 ). Two copies of this region led to a greater ratio of induction relative to a single copy (compare plasmids (Fig. 2, plasmid 1) . A fragment containing the 5'-most 141 bp (Fig. 2, plasmid Liver-Specific Cellular Factors Interact with the PPRE. Mobility-shift experiments were performed to determine whether cellular factors interact with the PPRE. Incubation of a probe (-3040 to -2845, Fig. 2 ) with nuclear extract from H4IIEC3 cells resulted in the formation of two major protein-DNA complexes, designated C1 and C2 (Fig. 4A, lane d) . Two treated H4IIEC3 cells (Fig. 4B, lanes b and c) , suggesting that the quantitative and qualitative differences in protein-DNA interactions observed in these extracts with the PPRE probe were related to treatment with ciprofibrate and not to differences in the integrity of the extracts. HeLa and BSC40 extracts also were capable of forming Oct-l-containing complexes (Fig. 4B, lanes a and d) , supporting the observation that these cells do not contain specific factors capable of interacting with the PPRE.
Competition experiments were carried out to assess the specificity of these protein-DNA interactions. A 50-or 100-fold molar excess of unlabeled -3040 to -2845 probe DNA reduced the amounts of both the C1 and C2 complexes (Fig. 4C, lanes c and d) ; however, nonspecific yeast DNA (lanes i andj) was unable to inhibit complex formation. Thus, liver nuclear factors interact with the PPRE in a sequencespecific manner.
Competitor DNA corresponding to -3159 to -2900 (Fig.  4C , lanes e and f), which overlaps the 5' end of the PPRE by 141 nucleotides, blocked formation of both the C1 and C2 complexes as effectively as did the homologous -3040 to -2845 DNA. In addition, competitor DNA -2928 to -2751, which overlaps the 3' end ofthe PPRE by 84 nucleotides, was also able to inhibit complex formation, although less efficiently (lanes g and h) . The 
DISCUSSION
The elucidation of the mechanism by which ciprofibrate and other peroxisome proliferators modulate gene expression and the relationship of this altered expression to hepatic tumorigenesis requires the identification of promoter elements and transcription factors responsible for mediating the biological response to these non-genotoxic agents. Toward this goal we have identified a PPRE upstream of the rat HD gene. This element functions independently of orientation and position, can confer responsiveness on a heterologous promoter, and interacts with liver cell-specific factors in a sequence-specific manner. Recently, the gene encoding rat liver peroxisomal AOX has been shown to contain a PPRE (18, 35 ) that functions in a manner similar to that described here for the HD gene PPRE. Recently, several members of the steroid hormone receptor superfamily that are activated by peroxisome proliferators have been cloned from mouse (16) and Xenopus (17) . These PPARs were shown to transactivate expression of genes containing the rat AOX PPRE in a peroxisomeproliferator dependent manner (17, 18) and to recognize the sequence TGACCT, the consensus half-site for several nuclear hormone receptors (36, 37) . Interestingly, the HD PPRE contains several sequences similar to this consensus half-site, which are present in the direct repeat array TJGAC(J.A/ TTGAaCTA/TtACCTA (nucleotides -2948 to -2926; Fig.  3, stippling) .
While the TGACCT direct repeat array in the HD PPRE may be required for induction, it is by itself insufficient for maximal induction (Fig. 2, construct i) . Therefore, if these PPAR(s), which have been demonstrated to bind to and to activate the AOX PPRE, also bind to the HD PPRE, maximal transcriptional induction for the HD PPRE may depend on cooperativity with other proteins bound to distal sites in the PPRE. The fact that both the -3159 to -2900 and the -2928 to -2751 promoter region could compete for factor binding but were insufficient for maximal ciprofibrate-mediated induction suggests that the properjuxtaposition of several sites may be required for full response. In this context, it will be of interest to determine the nature of the protein-DNA interactions on the HD PPRE and the possible interplay of ligand-activated receptors both in protein-DNA complex formation and in the coordinated transcriptional activation of the other members of the j-oxidation pathway.
